Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
- Status
- AVAILABLE
- Phase
- N/A
Clinical Trials Related to PDAC
Related studies linked through entity extraction aliases.
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- RECRUITING
- Phase
- PHASE3
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer
- Status
- RECRUITING
- Phase
- NA
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
- Status
- RECRUITING
- Phase
- N/A
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Mesopancreas Study in Pancreatic Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1